0001654954-26-005005
SEC filingOperating losses narrowed 17% YoY to -$5.3M through cost discipline in supplies, stock compensation, and public relations, while net cash burn eased slightly to -$8.0M, though going concern doubts persist from recurring losses and limited cash.
Cash flow from operations used -$8.0 million, an improvement from -$8.5 million YoY, with free cash flow matching due to zero capital expenditures—down from $33K prior year. This moderation in burn rate underscores expense controls, yet liquidity remains strained. The company depends on securities sales for funding and flags substantial doubt about its going concern status due to historical and expected future losses plus limited cash balances.
Overall, cost rationalization mitigated loss expansion in this pre-revenue biotech, but persistent cash needs and going concern warnings highlight reliance on capital markets for survival and advancement.